What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Oral Capsule to be administered at each specific dose level within each cohort”In the company’s words, NCT07558668 on ClinicalTrials.gov
- Tested for
- Moderate to Severe Atopic Dermatitis
- Main trialPhase 1
- “The purpose of this study is to evaluate the study drug, SYX-5219, in a multi-part First-in-Human (FiH) study to be conducted in healthy volunteers and participants with Atopic Dermatitis (AD). The objectives of this study are to determine the safety, tolerability and levels of SYX-5219 in the blood and urine when SYX-5219 is given in each part of the study (SAD, MAD, Food Effect and Participants with AD). The study will be split into up to 3 parts as follows: * Part 1 - Single Ascending Dose (SAD) and Food Effect in healthy volunteers * Part 2 - Multiple Ascending Dose (MAD) in healthy…”In the company’s words, NCT07558668 on ClinicalTrials.gov
Other drugs for Moderate to Severe Atopic Dermatitis
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 30 Aug 2026 | A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026